Market revenue in 2024 | USD 102,014.2 million |
Market revenue in 2030 | USD 178,958.9 million |
Growth rate | 10% (CAGR from 2025 to 2030) |
Largest segment | Cancer |
Fastest growing segment | Musculoskeletal Conditions |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cancer, Neurological Conditions, Cardiovascular Conditions, Musculoskeletal Conditions, Hematologic Disorders, Infectious Diseases, Metabolic Diseases, Endocrine Disorders |
Key market players worldwide | Roche Holding AG, Pfizer Inc, PTC Therapeutics Inc, AstraZeneca PLC, Novartis AG ADR, Takeda Pharmaceutical Co Ltd, Bayer AG, AbbVie Inc, Merck & Co Inc, Bristol-Myers Squibb Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare diseases treatment market will help companies and investors design strategic landscapes.
Cancer was the largest segment with a revenue share of 30.72% in 2024. Horizon Databook has segmented the U.S. rare diseases treatment market based on cancer, neurological conditions, cardiovascular conditions, musculoskeletal conditions, hematologic disorders, infectious diseases, metabolic diseases, endocrine disorders covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. rare diseases treatment market , including forecasts for subscribers. This country databook contains high-level insights into U.S. rare diseases treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account